Loading clinical trials...
Loading clinical trials...
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
Conditions
Interventions
ARV-110 in Combination with Abiraterone
Locations
18
United States
Clinical Trial Site
Santa Monica, California, United States
Clinical Trial Site
New Haven, Connecticut, United States
Clinical Trial Site
Fort Myers, Florida, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Columbus, Ohio, United States
Clinical Trial Site
Portland, Oregon, United States
Start Date
February 1, 2022
Primary Completion Date
July 2, 2024
Completion Date
April 10, 2025
Last Updated
July 25, 2025
NCT07115914
NCT05327465
NCT06165302
NCT06242119
NCT05563558
NCT06260410
Lead Sponsor
Arvinas Androgen Receptor, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions